Extracorporeal Membrane Oxygenation (ECMO) Market Size, Growth and Share Forecasted to Grow 4-6% from 2024 to 2029

Extracorporeal Membrane Oxygenation (ECMO) is a life-support system used for patients with severe respiratory and/or cardiac failure. It oxygenates the blood outside the body, allowing the heart and lungs to recover from serious illness or injury. According to the Extracorporeal Life Support Organization (ELSO) registry, by 2022, the registry had enrolled its 200,000th ECMO patient and 100,000th patient discharged alive.

The Rising Incidence of Cardiovascular and Pulmonary Diseases to Drive Market Growth

The rising incidence of cardiovascular and pulmonary diseases significantly drives the ECMO market due to the critical role ECMO plays in treating severe cases of these conditions. Cardiovascular diseases, including heart attacks and cardiogenic shock, often lead to acute heart failure, necessitating immediate life-support interventions. Similarly, pulmonary diseases such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and severe pneumonia can result in life-threatening respiratory failure, requiring advanced respiratory support. According to World Health Organization (WHO) chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019, while an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. As the global prevalence of these diseases increases, largely due to aging populations, lifestyle factors, and environmental issues, the demand for ECMO as a critical care solution is rising. Furthermore, pandemics like COVID-19 have underscored the importance of ECMO in managing severe respiratory failures, thereby boosting its adoption. Healthcare providers are increasingly recognizing ECMO's potential to improve survival rates in critical patients. Consequently, hospitals and healthcare systems are investing in ECMO technology and training, further propelling the market growth. This increased demand aligns with the broader trend of enhancing critical care infrastructure to better manage the growing burden of cardiopulmonary disease.

“ECMO is a game-changer, allowing us to support the heart and lungs while treating the underlying condition or preparing for transplant. By providing vital support to damaged organs, ECMO has dramatically improved survival rates for the most critically ill patients"- Pulmonologist, Leading Academic Medical Center, United States

Technological Advancements Likely to Boost the Adoption of ECMO Market

Technological advancements play a pivotal role in propelling the market for ECMO technology. The introduction of innovative features such as portable and miniaturized systems has revolutionized ECMO equipment, making it more accessible and efficient. These advancements have not only enhanced the portability and usability of ECMO machines but have also improved patient outcomes by offering more precise and effective support to critically ill individuals. Additionally, the development of components like improved rotary pumps, dual lumen cannula, and advanced oxygenators has streamlined the use of ECMO machines, making them more user-friendly and effective in providing circulatory and respiratory support. Moreover, technological progress has led to the introduction of surface coatings that reduce thrombogenicity, minimize the need for continuous anticoagulation, and lower the incidence of related complications, enhancing the safety and efficacy of ECMO procedures. These advancements not only drive market growth by expanding the application of ECMO technology but also contribute to improved patient care, making ECMO a more viable and effective treatment option for individuals with severe cardio-pulmonary disorders and respiratory problems globally platform.

To learn more about this report, download the PDF brochure

Product Innovations are Driving the ECMO Market

The ECMO market is technology-driven and is marked by constant product enhancements/innovations. For instance,

• In November 2022, LivaNova PLC received 510(k) clearance for ECMO from USFDA for LifeSPARC, the Company’s next-generation Advanced Circulatory Support (ACS) pump and controller system
• In July 2021, Xenios AG received received approval from the National Medical Products Administration (NMPA) in China for the Xenios Console and patient kits for ECMO therapy.
• In February 2020, Fresenius Medical care AG & Co. KGaA received US FDA clearance Novalung, a system designed to provide support for the heart and lungs in cases of acute respiratory or cardiopulmonary failure.

China Expected to be a Major Growth Engine in ECMO Market

China is expected to be a major growth engine in the ECMO market. This is primarily due to its rapidly expanding healthcare infrastructure and increasing investments in advanced medical technologies. The Chinese government’s strong commitment to improving healthcare services, coupled with rising healthcare expenditure, creates a conducive environment for the adoption of ECMO systems. Additionally, the increasing prevalence of cardiopulmonary diseases in China, driven by factors such as urbanization, pollution, and lifestyle changes, underscores the need for advanced critical care solutions like ECMO. The country's large population base provides a significant patient pool, further driving demand. Furthermore, China's focus on medical innovation and its burgeoning medical research sector facilitates the development and deployment of sophisticated ECMO technologies. Training programs and partnerships between local hospitals and international ECMO providers also enhance the capability of healthcare professionals to effectively use these systems. As a result, China is poised to become a pivotal player in the global ECMO market, with substantial growth expected in the coming years due to these favourable conditions.

The Chinese market is a dynamic and lucrative environment, driven by significant market development opportunities. For instance,

• In February 2023, Revive-I, China's domestically developed device of RocketMedical Co., Ltd. (Rocket Medical), was launched in the country.

Component Type Segment Analysis

The ECMO market comprises of: Pumps, Oxygenator, Controllers, Cannula, and Accessories. Oxygenators hold a high market share followed by pumps. Oxygenators have an indispensable function in the ECMO system. An oxygenator, often referred to as an artificial lung, is responsible for exchanging gases by oxygenating the blood and removing carbon dioxide. The quality and performance of the oxygenator directly impact the overall success of ECMO therapy. Oxygenators are subject to intense research and development efforts aimed at improving biocompatibility, gas exchange efficiency, and longevity. Innovations such as coated hollow fiber membranes and advanced materials have enhanced their performance, making them a critical component of ECMO systems. The necessity for frequent replacement and the relatively high cost of oxygenators also contribute to their substantial market share. Given their pivotal role in patient outcomes and the need for continual advancement, oxygenators represent a significant segment within the ECMO market.

Pumps play a critical role in the functioning of the entire ECMO system. Pumps are essential components of ECMO devices, facilitating the oxygenation process. The high market share of pumps can be attributed to their high cost and consumption, reflecting their importance in ECMO procedures. These pumps come in various types, including impeller and centrifugal pumps, tailored to different ECMO techniques based on specific requirements. The increased utilization of pumps in ECMO procedures contributes to the growth of this segment, emphasizing its significance in the ECMO machine market.

To learn more about this report, download the PDF brochure

Modality Type Segment Analysis

The ECMO market can be analyzed based on modality types, such as Veno-Arterial, Veno-Venous, and Arterio-Venous. The veno-arterial segment accounted for the largest market share and is expected to grow at a healthy CAGR over the forecast period. VA ECMO is used primarily for patients with severe cardiac failure or cardiogenic shock, conditions that necessitate immediate and robust intervention to sustain life. The ability of VA ECMO to take over the function of both the heart and lungs makes it indispensable in acute care settings, especially in cases of cardiac arrest, severe myocardial infarction, or heart failure. Hospitals and healthcare facilities heavily invest in VA ECMO systems because of their life-saving potential and broad application in cardiac emergencies. The high cost associated with these complex systems and their usage in intensive care units (ICUs) contribute to a larger market share. Additionally, the rising incidence of cardiac diseases globally further drives the demand for VA ECMO, solidifying its substantial market presence. Veno-Venous (VV) ECMO also commands a considerable market share, primarily due to its specialized application in severe respiratory failure. The increased prevalence of respiratory illnesses and the high mortality associated with severe respiratory failure underscore the importance of VV ECMO in clinical practice.

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting both organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share. For instance,

• In September 2023, Inspira Technologies launched its Next Generation Liby System, an extracorporeal membrane oxygenation system with potential advantages that may improve usability and patient care.
• In October 2021, Getinge launched Rotaflow II extracorporeal life support system can be used for both veno-arterial (VA) and veno-venous (VV) ECMO.

• In April 2020, Abiomed aquired Breethe, a developer of an ECMO system, to enhance its product portfolio for patients with respiratory failure, cardiogenic shock, and conditions like ARDS, H1N1, SARS, or COVID-19.

The ECMO market is expected to gain further momentum in the coming years due to technological advancements, rising R&D investments, new product launches, and aggressive organic and inorganic growth strategies followed by the players.

Competitive Landscape Analysis: ECMO Market

The global ECMO market is marked by the presence of established market players such as Fresenius Medical Care AG & Co. KGaA, Getinge Group, Medtronic plc, LivaNova plc, Abiomed, Inc. (a Johnson & Johnson business), Terumo Corporation, EUROSETS, Braile Biomédica, and MicroPort Scientific Corporation, among others.

Get a sample report for competitive landscape analysis

Future Outlook of the ECMO Market

The global ECMO market is expected to gain further momentum in the coming years due rising incidences of cardiopulmonary diseases, technological advancements in ECMO systems, increased awareness and adoption, favourable reimbursement policies, and expanding applications in paediatrics and non-traditional indications. Innovations in portable and efficient devices, coupled with enhanced training and integration with digital health technologies, further propel market growth.

Key Strategic Questions Addressed

• What is the market size & forecast for the Global ECMO Market?

• What are the historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the Global ECMO Market?

• How has COVID-19 impacted the Global ECMO Market?

• What are the major growth drivers, restraints/challenges impacting the market?

• What are the opportunities prevailing in the market?

• What is the investment landscape?

• Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?

• Who are the major players operating in the market? What is the competitive positioning of key players?

• Who are the new players entering the market?

• What are the key strategies adopted by players?